Cantor Fitzgerald Reiterates Overweight on Celldex Therapeutics, Maintains $67 Price Target

Benzinga · 03/22 17:51
Cantor Fitzgerald analyst Kristen Kluska reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and maintains $67 price target.